T2 BIOSYSTEMS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.72 USD | +1.92% |
|
+30.99% | -40.72% |
| 04-29 | Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating | MT |
| 04-23 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54.61 | 183.5 | 85.67 | 10.39 | 32.71 | - | - |
| Enterprise Value (EV) 1 | 54.61 | 183.5 | 85.67 | 10.39 | 32.71 | 32.71 | 32.71 |
| P/E ratio | -0.9 x | -3.18 x | -1.67 x | -0.12 x | -1.12 x | -3.21 x | -5.17 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.55 x | 10.1 x | 3.05 x | 0.47 x | 3.12 x | 1.41 x | 0.98 x |
| EV / Revenue | 6.55 x | 10.1 x | 3.05 x | 0.47 x | 3.12 x | 1.41 x | 0.98 x |
| EV / EBITDA | -1,127,928 x | -4,802,728 x | - | - | - | - | - |
| EV / FCF | -1.18 x | - | -2.17 x | -0.2 x | -0.97 x | -1.01 x | -1.02 x |
| FCF Yield | -84.5% | - | -46% | -490% | -103% | -99.1% | -98.4% |
| Price to Book | -1.74 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 9.34 | 29.6 | 33.2 | 73.2 | 8,793 | - | - |
| Reference price 2 | 5,850 | 6,200 | 2,581 | 142.0 | 3.720 | 3.720 | 3.720 |
| Announcement Date | 24/02/20 | 04/03/21 | 17/02/22 | 13/03/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.335 | 18.13 | 28.06 | 22.3 | 10.5 | 23.2 | 33.4 |
| EBITDA | -48.42 | -38.2 | - | - | - | - | - |
| EBIT 1 | -52.06 | -41.36 | -42.97 | -55.51 | -35 | -36.3 | -36.5 |
| Operating Margin | -624.57% | -228.11% | -153.16% | -248.87% | -333.33% | -156.47% | -109.28% |
| Earnings before Tax (EBT) 1 | -59.01 | -46.8 | -49.24 | -62.32 | -39.7 | -40.9 | -41.1 |
| Net income 1 | -59.01 | -46.8 | -49.24 | -62.65 | -39.7 | -40.9 | -41.1 |
| Net margin | -707.93% | -258.12% | -175.5% | -280.87% | -378.1% | -176.29% | -123.05% |
| EPS 2 | -6,500 | -1,950 | -1,550 | -1,228 | -3.310 | -1.160 | -0.7200 |
| Free Cash Flow 1 | -46.12 | - | -39.45 | -50.97 | -33.7 | -32.4 | -32.2 |
| FCF margin | -553.35% | - | -140.61% | -228.5% | -320.95% | -139.66% | -96.41% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 24/02/20 | 04/03/21 | 17/02/22 | 13/03/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.428 | 6.98 | 7.234 | 5.911 | 3.677 | 5.483 | 2.078 | 1.964 | 1.472 | 1.6 | 2.2 | 2.9 | 3.8 | 4.4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -12.21 | -10.28 | -14.86 | -15.02 | -15.8 | -9.834 | -13.69 | -13.05 | -11.1 | -8.5 | -8.7 | -8.9 | -8.9 | -9.1 |
| Operating Margin | -164.4% | -147.26% | -205.38% | -254.09% | -429.7% | -179.35% | -658.66% | -664.51% | -753.8% | -531.25% | -395.45% | -306.9% | -234.21% | -206.82% |
| Earnings before Tax (EBT) 1 | -13.96 | -12.14 | -16.5 | -18.03 | -17.38 | -10.41 | -17.96 | -6.347 | -15.42 | -9.7 | -9.9 | -10 | -10.1 | -10.2 |
| Net income 1 | -13.96 | -12.14 | -16.5 | -18.03 | -17.7 | -10.41 | -17.96 | -6.347 | -15.42 | -9.7 | -9.9 | -10 | -10.1 | -10.2 |
| Net margin | -187.96% | -173.98% | -228.02% | -305.09% | -481.51% | -189.91% | -864.53% | -323.17% | -1,047.89% | -606.25% | -450% | -344.83% | -265.79% | -231.82% |
| EPS 2 | -400.0 | -350.0 | -500.0 | -500.0 | -295.0 | -141.0 | -132.0 | -8.000 | -3.450 | -1.860 | -1.200 | -0.7000 | -0.5000 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 17/02/22 | 05/05/22 | 15/08/22 | 10/11/22 | 13/03/23 | 22/05/23 | 07/08/23 | 15/11/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -46.1 | - | -39.5 | -51 | -33.7 | -32.4 | -32.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -127% | - | - | - | - | - | - |
| Assets 1 | 46.4 | - | - | - | - | - | - |
| Book Value Per Share | -3,357 | - | - | - | - | - | - |
| Cash Flow per Share | -4,984 | - | - | - | - | - | - |
| Capex 1 | 0.76 | - | 0.46 | 0.34 | 0.4 | 0.8 | 1.1 |
| Capex / Sales | 9.13% | - | 1.64% | 1.52% | 3.81% | 3.45% | 3.29% |
| Announcement Date | 24/02/20 | 04/03/21 | 17/02/22 | 13/03/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.72
USD
Average target price
3
USD
Spread / Average Target
-19.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.72% | 32.71M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| +26.03% | 107B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B |
- Stock Market
- Equities
- TTOO Stock
- Financials T2 Biosystems, Inc.
